Exact Mass: 198.0753

Exact Mass Matches: 198.0753

Found 39 metabolites which its exact mass value is equals to given mass value 198.0753, within given mass tolerance error 0.0002 dalton. Try search metabolite list with more accurate mass tolerance error 4.0E-5 dalton.

Cymoxanil

Pesticide4_Cymoxanil_C7H10N4O3_(2E)-2-Cyano-N-(ethylcarbamoyl)-2-(methoxyimino)acetamide

C7H10N4O3 (198.0753)


CONFIDENCE standard compound; EAWAG_UCHEM_ID 112

   

5-Acetylamino-6-amino-3-methyluracil

N-(6-amino-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acetamide

C7H10N4O3 (198.0753)


5-Acetylamino-6-amino-3-methyluracil (AAMU) is one of caffeine major metabolites. Analysis of caffeine and its metabolites is of interest with respect to caffeine exposure, for kinetic and metabolism studies and for opportunistic in vivo estimation of drug metabolizing enzyme activity in humans and animals. Urinary caffeine metabolite ratios are used in humans to assess the activity of cytochrome P450 1A2 (CYP1A2), xanthine oxidase and N-acetyltransferase 2 (NAT2), which are involved in the activation or detoxification of various xenobiotic compounds, including carcinogens. Investigating the activity of these enzymes is of clinical relevance for assessing intra- and inter-individual differences in NAT2- and CYP1A2-mediated drug metabolism, and for evaluating the risk of developing specific exposure-related diseases. (PMID: 3506820, 15685651, 12534641) [HMDB] 5-Acetylamino-6-amino-3-methyluracil (AAMU) is one of caffeine major metabolites. Analysis of caffeine and its metabolites is of interest with respect to caffeine exposure, for kinetic and metabolism studies and for opportunistic in vivo estimation of drug metabolizing enzyme activity in humans and animals. Urinary caffeine metabolite ratios are used in humans to assess the activity of cytochrome P450 1A2 (CYP1A2), xanthine oxidase and N-acetyltransferase 2 (NAT2), which are involved in the activation or detoxification of various xenobiotic compounds, including carcinogens. Investigating the activity of these enzymes is of clinical relevance for assessing intra- and inter-individual differences in NAT2- and CYP1A2-mediated drug metabolism, and for evaluating the risk of developing specific exposure-related diseases. (PMID: 3506820, 15685651, 12534641).

   

6-amino-5[N-methylformylamino]-1-methyluracil

N-(6-amino-4-hydroxy-1-methyl-2-oxo-1,2-dihydropyrimidin-5-yl)ethanimidic acid

C7H10N4O3 (198.0753)


6-amino-5[N-methylformylamino]-1-methyluracil belongs to the family of Pyrimidones. These are compounds whose pyrimidine ring bears a ketone.

   

Terbuthylazine-TP CSCD692760 (LM3)

Terbuthylazine-TP CSCD692760 (LM3)

C7H10N4O3 (198.0753)


CONFIDENCE standard compound; UCHEM_ID 4177

   

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE10

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE10

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE20

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE20

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE30

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE30

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE40

5-Acetylamino-6-amino-3-methyluracil; LC-tDDA; CE40

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE10

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE10

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE20

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE20

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE30

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE30

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE40

6-Amino-5-formamido-1,3-dimethyluracil; LC-tDDA; CE40

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE0; CorrDec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE0; CorrDec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE10; CorrDec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE10; CorrDec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE30; CorrDec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE30; CorrDec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE0; MS2Dec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE0; MS2Dec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE10; MS2Dec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE10; MS2Dec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil; AIF; CE30; MS2Dec

5-Acetylamino-6-amino-3-methyluracil; AIF; CE30; MS2Dec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE0; MS2Dec

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE0; MS2Dec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE10; MS2Dec

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE10; MS2Dec

C7H10N4O3 (198.0753)


   

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE30; MS2Dec

5-Acetylamino-6-amino-3-methyluracil [M+Na]+; AIF; CE30; MS2Dec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE0; CorrDec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE0; CorrDec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE10; CorrDec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE10; CorrDec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE30; CorrDec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE30; CorrDec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE0; MS2Dec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE0; MS2Dec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE10; MS2Dec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE10; MS2Dec

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE30; MS2Dec

6-Amino-5-formamido-1,3-dimethyluracil; AIF; CE30; MS2Dec

C7H10N4O3 (198.0753)


   

3-ethyl-4-(methoxyamino)-2,5-dioxoimidazolidine-4-carbonitrile

3-ethyl-4-(methoxyamino)-2,5-dioxoimidazolidine-4-carbonitrile

C7H10N4O3 (198.0753)


   

1-ETHYL-6-IMINODIHYDROPYRIMIDINE-2,4,5(3H)-TRIONE 5-(O-METHYLOXIME)

1-ETHYL-6-IMINODIHYDROPYRIMIDINE-2,4,5(3H)-TRIONE 5-(O-METHYLOXIME)

C7H10N4O3 (198.0753)


   

1H-Imidazole-1-carboxylicacid,5-amino-4-(aminocarbonyl)-,ethylester(9CI)

1H-Imidazole-1-carboxylicacid,5-amino-4-(aminocarbonyl)-,ethylester(9CI)

C7H10N4O3 (198.0753)


   

6-morpholin-4-yl-2H-1,2,4-triazine-3,5-dione

6-morpholin-4-yl-2H-1,2,4-triazine-3,5-dione

C7H10N4O3 (198.0753)


   

6-Amino-5-formamido-1,3-dimethyluracil

Formamide,N-(6-amino-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)-

C7H10N4O3 (198.0753)


   

4-nitro-5-propyl-1H-pyrazole-3-carboxamide

4-nitro-5-propyl-1H-pyrazole-3-carboxamide

C7H10N4O3 (198.0753)


   

1H-1,2,4-Triazole-3-carboxylicacid,5-[(1-oxopropyl)amino]-,methylester(9CI)

1H-1,2,4-Triazole-3-carboxylicacid,5-[(1-oxopropyl)amino]-,methylester(9CI)

C7H10N4O3 (198.0753)


   

Theophylline monohydrate

Theophylline monohydrate

C7H10N4O3 (198.0753)


D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

Dimethyluric acid

Dimethyluric acid

C7H10N4O3 (198.0753)


   

AAMU

N-(6-amino-3-methyl-2,4-dioxo-1H-pyrimidin-5-yl)acetamide

C7H10N4O3 (198.0753)


   

6-amino-5[N-methylformylamino]-1-methyluracil

6-amino-5[N-methylformylamino]-1-methyluracil

C7H10N4O3 (198.0753)


   

Acetylaminoaminomethyluracil

Acetylaminoaminomethyluracil

C7H10N4O3 (198.0753)